Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background/Aim

Earlier treatment in axial spondyloarthritis (axSpA) was proposed to alter disease prognosis in this often-challenging condition. We aimed to assess the proportion of patients and prognostic factors associated with axSpA remission.

Objective

The aim was to determine the number of patients with Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) of <2.1 (inactive/moderate disease activity). We also evaluated global functioning and health using the Assessment of Spondyloarthritis International Society-Health Index (ASAS-HI).

Materials and Methods

Patients with axSpA who were receiving targeted synthetic/biological disease-modifying anti-rheumatic drug (ts/bDMARDs) treatments and visited the rheumatology units at two tertiary-care centers between December 2021 and December 2022 were prospectively interviewed. Data regarding patient demographics, disease features, active and previous ts/bDMARDs treatments, and disease activity scores were obtained. Patients were assessed using the ASDAS-CRP, ASDAS-erythrocyte sedimentation rate (ASDAS-ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and ASAS-HI.

Results

Overall, 60 patients with axSpA were included in this study (women, n = 35); 25 (41.7%) and 36 (62.1%) achieved an ASDAS-CRP of <2.1 and an ASAS-HI of ≤5 (good health), respectively. Out of the 60 patients, 75% (n = 45) were treated with anti-tumor necrosis factor. Factors associated with achieving the target ASDAS-CRP included age ( = 0.019), sex ( = 0.015), employment status ( = 0.015), education level ( = 0.030), and the number of previous ts/bDMARDs treatments ( = 0.019). Additionally, the ASDAS-CRP strongly correlated with spinal pain and moderately correlated with the ASAS-HI, BASDAI, and the number of previous ts/bDMARDs treatments.

Conclusions

Remission was observed in 41.7% of patients, indicating a challenge in achieving target disease activity. However, 62.1% attained good health. Achieving remission was associated with younger age, male sex, a higher level of education, lower level of spinal pain, better global function by ASAS-HI, being employed and receiving their first treatment with ts/bDMARDs ( non-biologic switchers) at the time of interview. Our findings may potentially improve disease prognosis with the earlier use of ts/bDMARDs in those without favorable features by implementing an early axSpA intervention strategy.

© 2025 The Author(s). Published by Bentham Science Publishers. 
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971326045241016070431
2024-10-21
2025-09-01

  • From This Site

    /content/journals/crr/10.2174/0115733971326045241016070431
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/crr/21/4/CRR-21-4-07.html?itemId=/content/journals/crr/10.2174/0115733971326045241016070431&mimeType=html&fmt=ahah

References

  1. SchwartzmanS. RudermanE.M. A road map of the axial spondyloarthritis continuum.Mayo Clin. Proc.202297113414510.1016/j.mayocp.2021.08.00734801248
     [Google Scholar]
  2. van de SandeM.G.H. ElewautD. Pathophysiology and immunolgical basis of axial spondyloarthritis.Best Pract. Res. Clin. Rheumatol.202337310189710.1016/j.berh.2023.10189738030467
     [Google Scholar]
  3. MagreyM.N. DanveA.S. ErmannJ. WalshJ.A. Recognizing axial spondyloarthritis: A guide for primary care.Mayo Clin. Proc.202095112499250810.1016/j.mayocp.2020.02.00732736944
     [Google Scholar]
  4. MichelenaX. López-MedinaC. Marzo-OrtegaH. Non-radiographic versus radiographic axSpA: What’s in a name?Rheumatology (Oxford)202059iv18iv2410.1093/rheumatology/keaa42233053190
     [Google Scholar]
  5. D’AngeloS. SalvaraniC. MarandoF. GualbertiG. NovelliL. CurradiG. TripepiG. PitinoA. RamondaR. MarchesoniA. Residual disease in patients with axial spondyloarthritis: A post-hoc analysis of the QUASAR study.J. Clin. Med.20221112355310.3390/jcm1112355335743623
     [Google Scholar]
  6. GohY. KwanY.H. LeungY.Y. FongW. CheungP.P. A cross-sectional study on factors associated with poor work outcomes in patients with axial spondyloarthritis in Singapore.Int. J. Rheum. Dis.201922112001200810.1111/1756‑185X.1369631576680
     [Google Scholar]
  7. Pina VegasL. SbidianE. WendlingD. GoupilleP. FerkalS. Le CorvoisierP. GhalehB. LucianiA. ClaudepierreP. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: Results from the DESIR cohort.Rheumatology (Oxford)20226141487149510.1093/rheumatology/keab56534270707
     [Google Scholar]
  8. SieperJ. LandewéR. MagreyM. AndersonJ.K. ZhongS. WangX. LertratanakulA. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.RMD Open201951e00091710.1136/rmdopen‑2019‑00091731245052
     [Google Scholar]
  9. BubováK. ForejtováŠ. ZegzulkováK. GregováM. HušákováM. FilkováM. HořínkováJ. GatterováJ. TomčíkM. SzczukováL. PavelkaK. ŠenoltL. Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: Baseline clinical characteristics and subset differences in a single-centre cohort.BMJ Open201994e02471310.1136/bmjopen‑2018‑02471330944131
     [Google Scholar]
  10. BedaiwiM.K. AlRasheedR.F. Bin ZuairA. AlqurtasE.M. BaeshenM.O. OmairM.A. A cross-sectional study on clinical characteristics of Saudi axial spondylarthritis: Preliminary results.Eur. Rev. Med. Pharmacol. Sci.202125165241524734486699
     [Google Scholar]
  11. UlasS.T. ProftF. DiekhoffT. RiosV. RademacherJ. ProtopopovM. GreeseJ. EshedI. AdamsL.C. HermannK.G.A. OhrndorfS. PoddubnyyD. ZiegelerK. Sex-specific diagnostic efficacy of MRI in axial spondyloarthritis: Challenging the ‘One Size Fits All’ notion.RMD Open202394e00325210.1136/rmdopen‑2023‑00325237899091
     [Google Scholar]
  12. RamiroS. NikiphorouE. SeprianoA. OrtolanA. WebersC. BaraliakosX. LandewéR.B.M. Van den BoschF.E. BotevaB. BremanderA. CarronP. CiureaA. van GaalenF.A. GéherP. GenslerL. HermannJ. de HoogeM. HusakovaM. KiltzU. López-MedinaC. MachadoP.M. Marzo-OrtegaH. MoltoA. Navarro-CompánV. NissenM.J. Pimentel-SantosF.M. PoddubnyyD. ProftF. RudwaleitM. TelkmanM. ZhaoS.S. ZiadeN. van der HeijdeD. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.Ann. Rheum. Dis.2023821193410.1136/ard‑2022‑22329636270658
     [Google Scholar]
  13. van der HeijdeD. LieE. KvienT.K. SieperJ. Van den BoschF. ListingJ. BraunJ. LandewéR. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.Ann. Rheum. Dis.200968121811181810.1136/ard.2008.10082619060001
     [Google Scholar]
  14. ØrnbjergL.M. LindeL. GeorgiadisS. RasmussenS.H. LindströmU. AsklingJ. MichelsenB. GiuseppeD.D. WallmanJ.K. PavelkaK. ZávadaJ. NissenM.J. JonesG.T. RelasH. PiriläL. TomšičM. RotarZ. GeirssonA.J. GudbjornssonB. KristianslundE.K. van sder Horst-BruinsmaI. LoftA.G. LaasK. IannoneF. CorradoA. CiureaA. SantosM.J. SantosH. CodreanuC. AkkocN. GunduzO.S. GlintborgB. ØstergaardM. HetlandM.L. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.Semin. Arthritis Rheum.20225615208110.1016/j.semarthrit.2022.15208135985172
     [Google Scholar]
  15. GeorgiadisS. ØrnbjergL.M. MichelsenB. KvienT.K. Di GiuseppeD. WallmanJ.K. ZávadaJ. ProvanS.A. KristianslundE.K. RodriguesA.M. SantosM.J. RotarŽ. PirkmajerK.P. NordströmD. MacfarlaneG.J. JonesG.T. van der Horst-BruinsmaI. HellamandP. ØstergaardM. HetlandM.L. Cut-offs for disease activity states in axial spondyloarthritis with ankylosing spondylitis disease activity score (ASDAS) based on c-reactive protein and ASDAS based on erythrocyte sedimentation rate: Are they interchangeable?J. Rheumatol.202451767367710.3899/jrheum.2023‑121738621792
     [Google Scholar]
  16. ZochlingJ. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), bath ankylosing spondylitis disease activity index (BASDAI), bath ankylosing spondylitis functional index (BASFI), bath ankylosing spondylitis global score (BAS-G), bath ankylosing spondylitis metrology index (BASMI), dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQ-S).Arthritis Care Res. (Hoboken)201163S11S47S5810.1002/acr.2057522588768
     [Google Scholar]
  17. van WeelyS.F.E. van DenderenJ.C. SteultjensM.P.M. van der LeedenM. NurmohamedM.T. DekkerJ. DijkmansB.A.C. van der Horst-Bruinsmai.e. Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis.Arthritis Res. Ther.2012142R5210.1186/ar376522401146
     [Google Scholar]
  18. El MiedanyY. YoussefS. MehannaA. ShebryaN. Abu GamraS. El GaafaryM. Defining disease status in ankylosing spondylitis: Validation and cross-cultural adaptation of the Arabic bath ankylosing spondylitis functional index (BASFI), the bath ankylosing spondylitis disease activity index (BASDAI), and the bath ankylosing spondylitis global score (BASG).Clin. Rheumatol.200827560561210.1007/s10067‑007‑0755‑218180979
     [Google Scholar]
  19. RostomS. BenbouaazaK. AmineB. BahiriR. Ibn YacoubY. Ali Ou AllaS. AbouqalR. Hajjaj-HassouniN. Psychometric evaluation of the Moroccan version of the bath ankylosing spondylitis functional index (BASFI) and bath ankylosing spondylitis disease activity index (BASDAI) for use in patients with ankylosing spondylitis.Clin. Rheumatol.201029778178810.1007/s10067‑010‑1431‑520383548
     [Google Scholar]
  20. Di CarloM. LatoV. CarottiM. SalaffiF. Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis.Health Qual. Life Outcomes20161417810.1186/s12955‑016‑0463‑127188166
     [Google Scholar]
  21. KiltzU. van der HeijdeD. BoonenA. Bautista-MolanoW. Burgos-VargasR. ChiowchanwisawakitP. DuruozT. El-ZorkanyB. EssersI. GaydukovaI. GéherP. GossecL. GrazioS. GuJ. KhanM.A. KimT.J. MaksymowychW.P. Marzo-OrtegaH. Navarro-CompánV. OlivieriI. PatrikosD. Pimentel-SantosF.M. SchirmerM. van den BoschF. WeberU. ZochlingJ. BraunJ. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS health index and the environmental item set: Translation and cross-cultural adaptation into 15 languages.RMD Open201622e00031110.1136/rmdopen‑2016‑00031127752358
     [Google Scholar]
  22. KiltzU. WendlingD. BraunJ. ASAS health index: The “All in One” for spondyloarthritis evaluation?J. Rheumatol.202047101457146010.3899/jrheum.20070833004479
     [Google Scholar]
  23. MinH.K. LeeJ. JuJ.H. ParkS.H. KwokS.K. Predictors of assessment of spondyloarthritis international society (ASAS) health index in axial spondyloarthritis and comparison of ASAS health index between ankylosing spondylitis and nonradiographic axial spondyloarthritis: Data from the catholic axial spondyloarthritis cohort (CASCO).J. Clin. Med.20198446710.3390/jcm804046730959846
     [Google Scholar]
  24. RegiererA.C. WeißA. KiltzU. SieperJ. SchwarzeI. Bohl-BühlerM. KellnerH. PoddubnyyD. ZinkA. BraunJ. ListingJ. StrangfeldA. The sensitivity to change of the ASAS health index in an observational real-life cohort study.J. Rheumatol.202350218519110.3899/jrheum.22021235914790
     [Google Scholar]
  25. SieperJ. RudwaleitM. BaraliakosX. BrandtJ. BraunJ. Burgos-VargasR. DougadosM. HermannK-G. LandewéR. MaksymowychW. van der HeijdeD. The assessment of spondyloarthritis international society (ASAS) handbook: A guide to assess spondyloarthritis.Ann. Rheum. Dis.200968ii1ii4410.1136/ard.2008.10401819433414
     [Google Scholar]
  26. MachadoP.M. LandewéR. van der HeijdeD. Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states.Ann. Rheum. Dis.201877101539154010.1136/annrheumdis‑2018‑21318429453216
     [Google Scholar]
  27. KaltsonoudisE. PelechasE. VoulgariP. DrososA. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: An 18-month comparative open-label study.J. Clin. Med.20198795610.3390/jcm807095631269678
     [Google Scholar]
  28. KiltzU. van der HeijdeD. BoonenA. AkkocN. Bautista-MolanoW. Burgos-VargasR. WeiJ.C.C. ChiowchanwisawakitP. DougadosM. DuruozM.T. ElzorkanyB.K. GaydukovaI. GenslerL.S. GilioM. GrazioS. GuJ. InmanR.D. KimT.J. Navarro-CompanV. Marzo-OrtegaH. OzgocmenS. Pimentel dos SantosF. SchirmerM. StebbingsS. Van den BoschF.E. van TubergenA. BraunJ. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.Ann. Rheum. Dis.20187791311131710.1136/annrheumdis‑2017‑21207629858176
     [Google Scholar]
  29. ShimabucoA.Y. GonçalvesC.R. MoraesJ.C.B. WaisbergM.G. RibeiroA.C.M. Sampaio-BarrosP.D. Goldenstein-SchainbergC. BonfaE. SaadC.G.S. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors.Adv. Rheumatol.20185814010.1186/s42358‑018‑0040‑x30657103
     [Google Scholar]
  30. ChenH.H. ChenY.M. LaiK.L. HsiehT.Y. HungW.T. LinC.T. TsengC.W. TangK.T. ChouY.Y. WuY.D. HuangC.Y. HsiehC.W. HuangW.N. ChenY.H. Gender difference in ASAS HI among patients with ankylosing spondylitis.PLoS One2020157e023567810.1371/journal.pone.023567832645080
     [Google Scholar]
  31. OmairM.A. AlDuraibiF.K. BedaiwiM.K. AbdulazizS. HusainW. El DessougiM. AlhumaidanH. Al KhabbazH.J. AlahmadiI. OmairM.A. Al SalehS. AlismaelK. Al AwwamiM. Prevalence of HLA-B27 in the general population and in patients with axial spondyloarthritis in Saudi Arabia.Clin. Rheumatol.20173671537154310.1007/s10067‑017‑3655‑028456926
     [Google Scholar]
  32. ZiadeN. Abi KaramG. MerhebG. MallakI. IraniL. AlamE. MessaykehJ. MenassaJ. Mroue’K. UthmanI. MasriA.F. GhorraP. WitteT. BaraliakosX. HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study.Int. J. Rheum. Dis.201922470871410.1111/1756‑185X.1348730729696
     [Google Scholar]
  33. Al-AttiaH.M. Al-AmiriN. HLA-B27 in healthy adults in UAE. An extremely low prevalence in Emirian Arabs.Scand. J. Rheumatol.199524422522710.3109/030097495091008787481586
     [Google Scholar]
  34. ZiadeN.R. HLA B27 antigen in Middle Eastern and Arab countries: Systematic review of the strength of association with axial spondyloarthritis and methodological gaps.BMC Musculoskelet. Disord.201718128010.1186/s12891‑017‑1639‑528662723
     [Google Scholar]
  35. FaveroM. OmettoF. BelluzziE. CozziG. ScagnellatoL. OlivieroF. RuggieriP. DoriaA. LorenzinM. RamondaR. Fetuin-A: A novel biomarker of bone damage in early axial spondyloarthritis. Results of an interim analysis of the SPACE study.Int. J. Mol. Sci.2023244320310.3390/ijms2404320336834615
     [Google Scholar]
  36. CiureaA. GötschiA. KisslingS. BernatschekA. BürkiK. ExerP. NissenM.J. MöllerB. SchererA. MicheroliR. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.RMD Open202392e00295610.1136/rmdopen‑2022‑00295637277211
     [Google Scholar]
  37. HelliwellP.S. GladmanD.D. ChakravartyS.D. KafkaS. KaryekarC.S. YouY. CampbellK. SweetK. KavanaughA. GenslerL.S. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.RMD Open202061e00114910.1136/rmdopen‑2019‑00114932209721
     [Google Scholar]
  38. KwokT.S.H. SuttonM. PereiraD. CookR.J. ChandranV. HaroonN. InmanR.D. GladmanD.D. Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis.Ann. Rheum. Dis.202281121678168410.1136/ard‑2022‑22253735973805
     [Google Scholar]
  39. RobinsonP.C. BrownM.A. The window of opportunity: A relevant concept for axial spondyloarthritis.Arthritis Res. Ther.201416310910.1186/ar456125167369
     [Google Scholar]
  40. MauroD. ForteG. PoddubnyyD. CicciaF. The role of early treatment in the management of axial spondyloarthritis: Challenges and opportunities.Rheumatol. Ther.2024111193410.1007/s40744‑023‑00627‑038108992
     [Google Scholar]
  41. Leirisalo-RepoM. What is the best treatment strategy for early RA?Best Pract. Res. Clin. Rheumatol.201327452353610.1016/j.berh.2013.10.00224315052
     [Google Scholar]
  42. QuinnM.A. ConaghanP.G. EmeryP. The therapeutic approach of early intervention for Rheumatoid arthritis: What is the evidence?Br. J. Rheumatol.200140111211122010.1093/rheumatology/40.11.121111709604
     [Google Scholar]
/content/journals/crr/10.2174/0115733971326045241016070431
Loading
Factors Associated with Axial Spondyloarthritis Remission in a Cohort of Saudi Patients with Longstanding Disease: A Multicenter Prospective Cohort Study
Curr. Rheumatol. Rev. 21, 435 (2025); https://doi.org/10.2174/0115733971326045241016070431
/content/journals/crr/10.2174/0115733971326045241016070431
/content/journals/crr/10.2174/0115733971326045241016070431
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Axial spondyloarthritis; biological therapy; disease activity index; prognosis; remission; treat-to-target

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test